G-BA — NSCLC

Dossier modules

• AMNOG_M1

  Module 1 — Summary

  required79%
• AMNOG_M2

  Module 2 — MoA & approved indication

  required84%
• AMNOG_M3

  Module 3 — ZVT, disease, prevalence, costs

  required82%
• AMNOG_M4

  Module 4 — Medical benefit vs ZVT (patient-relevant endpoints)

  required49%
• AMNOG_M5

  Module 5 — Full study reports (confidential)

  required97%

PICO questions (3)

1. G-BA-PICO-01g-ba_zvt
   P: Adults with metastatic NSCLC, PD-L1 TPS≥50%, no prior systemic therapy

   I: Test drug, monotherapy, q3w until progression

   C: pembrolizumab monotherapy; platinum doublet chemotherapy; atezolizumab

   O: overall survival, PFS, ORR, DoR, AEs ≥G3, HRQoL (EORTC QLQ-C30)
2. G-BA-PICO-02g-ba_zvt
   P: Adults with metastatic NSCLC, PD-L1 TPS≥50%, no prior systemic therapy

   I: Test drug, monotherapy, q3w until progression

   C: atezolizumab; platinum doublet chemotherapy

   O: overall survival, PFS, ORR, DoR, AEs ≥G3, HRQoL (EORTC QLQ-C30)
3. G-BA-PICO-03g-ba_zvt
   P: Adults with metastatic NSCLC, PD-L1 TPS≥50%, no prior systemic therapy

   I: Test drug, monotherapy, q3w until progression

   C: pembrolizumab monotherapy; platinum doublet chemotherapy; atezolizumab

   O: overall survival, PFS, ORR, DoR, AEs ≥G3, HRQoL (EORTC QLQ-C30)